Mahana Therapeutics announced last week (August 22) that it was entering into a multi-million dollar distribution and marketing partnership with the consumer health division of Bayer.
Leaders from some of the industry’s most notable companies are working together to streamline and automate IDMP workflow and come up with various standards.
Created via a joint effort with EY, the pharmaceutical company launched ASPIREs, a program intended to improve its clinical trial processes in numerous areas.
This month’s news on new hires, board launches, acquisitions, and other important news includes items on Pfizer, Javara, Clinical Ink, and other companies.
Bayer collaborates with Accenture on the Intient clinical platform, which integrates internal and external clinical data to accelerate drug development insights.
Organizations or individuals desiring change is often the reason for retirements, but the timing is often crucial and so it proved for two major institutions in the UK.
Bayer looks to boost investor confidence by cutting away its animal health unit, selected consumer health brands and a number of jobs to focus on its life sciences businesses.
The new season has brought a change in line-up for some companies with new hires and retirements, but for some it meant changing the rules to keep key players.
Janssen has confirmed plans to close a supply chain facility in HyangNam, while Bayer is transferring manufacturing operations from Ansung, South Korea, to Berlin, Germany.
Sanofi-Aventis had a €5bn ($6.6bn) bid for Solvay’s pharma business rejected, according to media reports, but several other companies are believed to be interested in the Belgian firm.
Germany's Bayer hopes that its pilot-scale production facility in
Halle, Saxony-Anhalt will help establish its tobacco plant-based
expression system as leader of the lucrative protein manufacturing
sector.
In the inevitable reshuffle that comes after a major acquisition,
Bayer's healthcare division has today announced plans to cut 30 per
cent of its drug pipeline.
Bayer has acquired Icon Genetics in a culmination of an existing
agreement between the two companies. The deal also solidifies
Bayer's direction as it soughts to strengthen its efforts to
produce specific plant-made pharmaceuticals.
Bayer Healthcare has announced that it will publish information
about its ongoing clinical trials, reinforcing the intention of the
pharmaceutical companies within the industry to provide an arena in
which they can publish information...
The fine chemicals business unit of Lanxess, which was spun-out
from Germany's Bayer earlier this year and provides custom
manufacturing services to the pharmaceutical and other industries,
has said it plans to expand its geographic...
German drugmaker Bayer last week put an end to speculation that it
is planning swingeing job cuts by conforming that it is planning to
axe 560 positions in Germany and the US as part of restructuring
its global pharmaceutical R&D...
Germany's Bayer has reported a mixed set of results for the second
quarter with fine chemicals offshoot Lanxess contributing to an
unexpected 44 per cent hike in earnings before interest and tax
(EBIT).
German chemical company Bayer has posted flat first-quarter 2004
sales, but said that the results were on track given the negative
effects of currency factors. Organic sales growth rose 8.6 per
cent, it claimed, and was driven mainly...
Germany chemical and pharmaceutical company Bayer has christened
its chemicals spin-off Lanxess, and says it is on schedule for a
stock market flotation early next year.
Bayer Fine Chemicals has developed a new way to make chiral
epoxides that could shorten reaction times and reduce the amount of
expensive catalysts used in the process.
The European Court of Justice in Luxembourg has thrown out
allegations by the European Commission that Bayer, the German
pharmaceutical firm, had established a cartel agreement with its
wholesalers to restrict the trade flow of its...
Germany's Bayer has received offers to buy NewCo, the newly-created
company including parts of its chemicals and polymers divisions,
but will still go ahead with plans to float it on the stock
exchange , according to the group's...
Bayer has managed to avoid posting a third quarter operating loss,
but may incur charges in the fourth quarter relating to its
decision to float its chemicals business on the stock exchange.
The long-awaited break-up of Germany's Bayer has finally come to
pass with the decision to float the group's chemicals business on
the stock exchange within the next 18 months. But will this be the
end of the story for the...
Germany's Bayer has continued the revamp of its business units by
setting up its chemicals, technology services and healthcare
activities as three separate legal entities. The move follows the
carve-out of Bayer CropScience a...
Bayer has reported a decline in net profits for the second quarter
of 2003, with analysts expressing concerns that litigations costs
could hold back full-year earnings.
Scotland's PPL has started a mass slaughter of its flock of sheep
engineered to produce alpha-1 antitrypsin in their milk. The cull
could spell the end of the firm's ambitions in transgenic
production.
